After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

From the Capital of France to the Capital of New York — a cutting-edge biotech firm that uses AI to research cancer ...

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

Starting up in a garage isn’t an option for life sciences companies that do things like analyze microbes and test saliva samples. They need laboratory space, which is in short supply in Minnesota.

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now. On April 13, Tom Lee, Fundstrat’s ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

The Fremont company sold extra shares at the top of its proposed range, and the stock jumped more than 30% in initial trading ...